Pre-clinical blocking of PD-L1 molecule, which expression is down regulated by NF-κB, JAK1/JAK2 and BTK inhibitors, induces regression of activated B-cell lymphoma

Pre-clinical blocking of PD-L1 molecule, which expression is down regulated by NF-κB, JAK1/JAK2 and BTK inhibitors, induces regression of activated B-cell lymphoma

Abstract Escape from immune control must be important in the natural course of B-cell lymphomas, especially for those with activation of NF-κB. The pre-clinical LMP1/CD40-expressing transgenic mouse model is characterized by B-cell specific CD40 signaling responsible for NF-κB continuous activation...

Full description

Bibliographic Details
Main Authors: Christelle Vincent-Fabert, Lilian Roland, Ursula Zimber-Strobl, Jean Feuillard, Nathalie Faumont
Format: Article
Language:English
Published: BMC 2019-08-01
Series:Cell Communication and Signaling
Subjects:
B-cell lymphomas
PD-L1
Immune surveillance
Online Access:http://link.springer.com/article/10.1186/s12964-019-0391-x

Internet

http://link.springer.com/article/10.1186/s12964-019-0391-x

Similar Items